The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.
Studies designed, executed and funded by Alkermes, Inc.
Showing 10 of 99 results
Sort by date:
Descending
Mar 2018
Antagonists in the medical management of opioid use disorders: historical and existing treatment strategies
The American Journal on Addictions
AUTHOR(S)
Dec 2017
Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation
Schizophrenia Research
AUTHOR(S)
Aug 2017
Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia
The Journal of Clinical Psychiatry
AUTHOR(S)
Jul 2017
A Phase-1 Study Comparing Pharmacokinetic and Safety Profiles of Three Different Dose Intervals of Aripiprazole Lauroxil
Psychopharmacology Bulletin
AUTHOR(S)
Jul 2017
Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil
Psychopharmacology Bulletin
AUTHOR(S)
Jun 2017
Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model
CNS Drugs
AUTHOR(S)
Jun 2017
Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison
Value in Health
AUTHOR(S)
May 2017
Aripiprazole Lauroxil: Pharmacokinetic Profile of This Long-Acting Injectable Antipsychotic in Persons With Schizophrenia
Journal of Clinical Psychopharmacology
AUTHOR(S)
Apr 2017
Long-Acting Injectable Naltrexone Induction: A Randomized Trial of Outpatient Opioid Detoxification With Naltrexone Versus Buprenorphine
American Journal of Psychiatry
AUTHOR(S)
Apr 2017
Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence
Journal of Addiction Medicine
AUTHOR(S)
